Top 15 Companies in Opioid Use Disorder (OUD) Market 2025: Strategic Overview and Future Trends (2024–2035)
RELEASE DATE: Sep 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Opioid Use Disorder (OUD) Market Size is projected to Grow from USD 3.5 Billion in 2024 to USD 10.6 Billion by 2035, at a CAGR of 10.6% during the forecast period 2025–2035. The market for Opioid Use Disorder (OUD) is in greater demand due to rising prevalence of opioid addiction, government initiatives and funding, and increased awareness and diagnosis.
Introduction
The Global Opioid Use Disorder (OUD) Market Size focuses on tackling the growing difficulties of opioid abuse and addiction. Opioids are synthetic medications that replicate natural opioid capabilities by attaching to receptors in the brain and body to alleviate pain. They consist of prescription pain medications, synthetic opioids, and heroin. Prescription opioids are necessary for managing acute pain from surgery or injury, chronic pain, cancer therapy, palliative care, and end-of-life care, but their abuse has become a major issue. Many patients rely on these prescriptions under medical supervision, but long-term usage frequently develops into dependence, making opioid use disorder a chronic illness characterized by relapses, impairments, and even death. The increasing incidence of chronic conditions, accidents, and cancer cases necessitating opioid prescriptions is driving market expansion, raising the danger of addiction. Furthermore, increased government and non-government initiatives to raise awareness about opioid usage and overdose are critical factors. The Department of Health and Human Services' 2022 funding for drug addiction prevention and treatment programs increases access to medication-assisted therapy (MAT). These combined forces continue to influence and grow the worldwide OUD market.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of the Opioid Use Disorder (OUD) Market.
Opioid Use Disorder (OUD) Market Size & Statistics
- The Market Size for Opioid Use Disorder (OUD) Was Estimated to be worth USD 3.5 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 10.6% between 2025 and 2035.
- The Global Opioid Use Disorder (OUD) Market Size is anticipated to reach USD 10.6 Billion by 2035.
- North America is expected to generate the highest demand during the forecast period in the Opioid Use Disorder (OUD) Market
- Asia Pacific is expected to grow the fastest during the forecast period in the Opioid Use Disorder (OUD) Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the Opioid Use Disorder (OUD) market. Asia Pacific is projected to witness strong revenue growth in the opioid use disorder market, driven by a rising elderly population, increasing awareness of accessible healthcare facilities, and a growing prevalence of chronic disorders across major regional countries during the forecast period.
North America is expected to generate the highest demand during the forecast period in the Opioid Use Disorder (OUD) market. North America leads the opioid use disorder market, driven by rising product launches, increased opioid prescriptions and consumption, and growing overdose fatalities. A well-established opioid industry and strong treatment infrastructure further support significant regional growth throughout the forecast period.
Top 10 Trends in the Opioid Use Disorder (OUD) Market
- Rising Adoption of Medication-Assisted Treatment (MAT)
- Long-Acting Injectable and Implantable Therapies
- Telemedicine and Digital Health Integration
- Government Funding and Policy Support
- Growing Focus on Overdose Prevention
- Emergence of Non-Opioid Alternatives
- Increased Public Awareness Campaigns
- Rising Clinical Trials and R&D Investment
- Expansion into Emerging Markets
- Integration of Behavioral and Holistic Therapies
1. Rising Adoption of Medication-Assisted Treatment (MAT)
Medication-Assisted Treatment (MAT), which combines medicines like methadone, buprenorphine, and naltrexone with counselling or behavioral treatment, is increasingly being utilized to treat OUD. MAT improves patient outcomes, lowers relapse rates, and promotes long-term rehabilitation, resulting in increased demand in healthcare systems worldwide.
2. Long-Acting Injectable and Implantable Therapies
Long-acting formulation innovations, such as injectables and implants, enable drugs to be released over several weeks or months. These medicines increase patient adherence, reduce daily dosage burdens, and lower the potential of abuse, making OUD therapy more effective and easier.
3. Telemedicine and Digital Health Integration
Telehealth platforms are changing OUD therapy by allowing for remote consultations, digital monitoring, and virtual counseling. These technologies provide access to care, particularly in rural or underserved areas, and assist patients in sticking to treatment programs without having to visit the clinic as frequently.
4. Government Funding and Policy Support
Governments throughout the world are raising resources and enacting legislation to address the opioid crisis. Initiatives such as funding for MAT programs, drug abuse prevention campaigns, and increased access to addiction treatment all contribute to market growth.
5. Growing Focus on Overdose Prevention
Efforts to prevent opioid overdoses, such as increased availability of naloxone and harm-reduction programs, are growing. These efforts not only save lives but also open up prospects for linked OUD therapies, which help to expand the total market.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the opioid use disorder (OUD) market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 25 Companies Leading the Opioid Use Disorder (OUD) Market
- Indivior PLC
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc. (Mylan N.V.)
- Hikma Pharmaceuticals PLC
- Camurus
- Assertio Therapeutics, Inc.
- Acadia Healthcare
- Amgen Inc.
- Bicycle Health
- Monument Inc.
- Pear Therapeutics
- Braeburn Pharmaceuticals
- Intas Pharmaceuticals
- Purdue Pharma L.P.
- Alkaloid AD Skopje
- Meda Pharma (Mylan subsidiary)
- Camurus AB (additional markets)
- Indivior PLC (regional expansions)
- Johnson & Johnson
- Novartis AG
- Eli Lilly and Company
1. Indivior PLC
Headquarters: North Chesterfield, Virginia, USA
Indivior PLC is an established pharmaceutical firm focused on the treatment of opioid use disorder (OUD). The firm is headquartered in North Chesterfield, Virginia, USA, and operates in over 20 countries, including Canada, the United Kingdom, Germany, Ireland, and Israel, assuring a broad global reach. Indivior's primary emphasis is on developing and commercializing opioid addiction drugs, particularly Suboxone and Sublocade, which are often used in medication-assisted therapy (MAT). The firm is a key player in the OUD industry, with a substantial percentage of its income coming from the United States, and it is known for creating recovery solutions and boosting patient access to effective medicines throughout the world.
2. Alkermes plc
Headquarters: Dublin, Ireland
Alkermes plc is a multinational biopharmaceutical firm based in Dublin, Ireland, having operations in the United States and Europe, including Massachusetts and Ohio. The firm focuses on the development of treatments for central nervous system problems such as addiction, psychiatric, and neurological conditions. Alkermes is well-known for Vivitrol, a long-acting injectable therapy used to treat opiate and alcohol dependency. By concentrating on new delivery systems that increase patient adherence, Alkermes has created a significant foothold in the opioid use disorder market. Its solutions improve recovery results and provide access to quality addiction treatments in diverse countries.
3. OREXO AB
Headquarters: Uppsala, Sweden
Orexo AB, based in Uppsala, Sweden, is a pharmaceutical firm that specializes in creating novel opioid medicines and digital health solutions. The firm is largely engaged in the United States, where it provides medications such as ZUBSOLV to treat opiate addiction. Orexo combines pharmaceutical and digital techniques to improve patient adherence, monitoring, and results in opioid use disorder care. Its emphasis on mixing medicine and digital assistance represents a contemporary, patient-centered approach to addiction treatment. Orexo is gaining traction in the worldwide OUD market by focusing on both therapeutic efficacy and accessibility, particularly in technologically sophisticated healthcare systems.
4. Titan Pharmaceuticals, Inc.
Headquarters: South San Francisco, California, USA
Titan Pharmaceuticals, Inc., situated in South San Francisco, California, USA, focuses on developing long-acting implantable medicines for chronic illnesses such as opioid use disorder. Probuphine, the company's main product, is a subdermal implant that delivers buprenorphine for six months to treat opioid addiction. Titan focuses on novel medication delivery systems that increase patient adherence, reduce daily dose, and lower the risk of abuse. While the corporation is largely based in the United States, it has license arrangements in Europe to increase its presence. Titan's pioneering implanted medicines help to make OUD therapy safer and more successful, while also strengthening the company's global footprint.
5. Mallinckrodt Pharmaceuticals
Headquarters: Dublin, Ireland
Mallinckrodt Pharmaceuticals is a multinational specialized pharmaceutical firm with legal headquarters in Dublin, Ireland, and operating hubs in Staines-upon-Thames, United Kingdom, and Hazelwood, Missouri, United States. The firm operates in North America, Europe, and the Asia-Pacific region, offering both generic and specialty drugs. Mallinckrodt manufactures opioid painkillers and is active in tackling opioid use disorder through treatment options and regulatory measures. The company's large worldwide presence, manufacturing capabilities, and experience with opioid medicines enable it to make a significant contribution to addiction treatment initiatives. Mallinckrodt is focused on safe, effective medications while negotiating the difficulties of the opioid business.
Are you ready to discover more about the opioid use disorder (OUD) market?
The report provides an in-depth analysis of the leading companies operating in the global opioid use disorder (OUD) market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Indivior PLC
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Alkermes plc
- OREXO AB
- Titan Pharmaceuticals, Inc.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc. (Mylan N.V.)
- Hikma Pharmaceuticals PLC
- Camurus
- Others.
Conclusion
The Global Opioid Use Disorder (OUD) Market Size is predicted to rise gradually, owing to rising opioid addiction rates, more awareness, and expanded treatment options. Medication-assisted therapies, including methadone, buprenorphine, and naltrexone, are becoming increasingly popular because of their demonstrated effectiveness in preventing relapse and promoting recovery. Government efforts, financing schemes, and telemedicine integration are boosting market development by making therapy more accessible. North America dominates the market, while Asia-Pacific is seeing significant expansion due to increased awareness and healthcare infrastructure. Overall, advancements in long-acting medicines, digital solutions, and integrated care models continue to change the worldwide OUD market.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?